Acute Porphyria Drug Database

M03BA03 - Methocarbamol
Propably not porphyrinogenic
PNP

Rationale
Methocarbamol does not show potential for interaction with CYP enzymes, and no porphyrinogenic effects have been identified.
Chemical description
Carbamatic acid ester
Therapeutic characteristics
Methocarbamol is a centrally acting muscle relaxant used in the treatment of musculoskeletal pain. It is administered orally or intravenously, and has a half-life of about 2 hours (SPC).
Metabolism and pharmacokinetics
Methocarbamol is metabolised in the liver, but data on the involvement of CYP enzymes are lacking (SPC, DrugBank). Methocarbamol did not show any potential for significant interactions with CYP3A4, CYP2C8, CYP2B6 or CYP2D6 in an in vitro study (Moody 2018).

Similar drugs
Explore alternative drugs in similar therapeutic classes M03B / M03BA or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙